Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.

@article{Wilson1999FiveDM,
  title={Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.},
  author={RobertJ. Wilson and Rolf Kubin and Isabel Ballin and K. M. Deppermann and Harry P. Bassaris and P. J. L{\'e}ophonte and Ad J. M. Schreurs and Antoni Torres and Bernd Sommerauer},
  journal={The Journal of antimicrobial chemotherapy},
  year={1999},
  volume={44 4},
  pages={
          501-13
        }
}
In this multinational, randomized, double-blind study, the efficacy and safety of a 5 day course of moxifloxacin 400 mg orally od was compared with that of a 7 day course of clarithromycin 500 mg orally bd. in 750 patients with acute exacerbations of chronic bronchitis, characterized by at least two of the symptoms: sputum purulence, increased sputum volume or increased dyspnoea. Seven days after the end of therapy, clinical cure was achieved for 89% (287 of 322) of efficacy-evaluable patients… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 57 CITATIONS, ESTIMATED 66% COVERAGE

Role of macrolide therapy in chronic obstructive pulmonary disease

  • International journal of chronic obstructive pulmonary disease
  • 2008
VIEW 1 EXCERPT
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2000
2017

CITATION STATISTICS

  • 1 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 38 REFERENCES

A double-blind, placebo and lomefloxacin controlled human volunteer study to determine the photosensitising potential of oral moxifloxacin (BAY 12-8039)

J. Ferguson, H. Al-Ajmi, R. Kubin, S. Daggett, P. S. Saggu
  • In Program and Abstracts of the Eighth International Congress on Infectious Diseases, Boston, USA,
  • 1998
VIEW 1 EXCERPT

Penetration of moxifloxacin into bronchial mucosa, epithelial lining fluid and alveolar macrophages following a single 400 mg oral dose

J. Andrews, D. Honeybourne, G. Jevons, R. Wise
  • In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA,
  • 1998
VIEW 1 EXCERPT

Similar Papers